Financhill
Sell
30

PFE Quote, Financials, Valuation and Earnings

Last price:
$26.33
Seasonality move :
3.61%
Day range:
$25.59 - $26.15
52-week range:
$24.48 - $31.54
Dividend yield:
6.49%
P/E ratio:
18.48x
P/S ratio:
2.33x
P/B ratio:
1.67x
Volume:
32.6M
Avg. volume:
42.2M
1-year change:
-6.76%
Market cap:
$147.6B
Revenue:
$63.6B
EPS (TTM):
$1.41

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
PFE
Pfizer
$17.3B $0.46 -3.03% 29.69% $31.32
AMGN
Amgen
$8.9B $5.08 8.14% 257.4% $315.95
ARVN
Arvinas
$62.8M -$0.96 71.95% -5.19% $45.26
MRNA
Moderna
$941.1M -$2.73 -19.37% -0.05% $54.14
REGN
Regeneron Pharmaceuticals
$3.7B $11.19 9.12% 53% $923.05
VKTX
Viking Therapeutics
-- -$0.27 -- -21.87% $99.29
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
PFE
Pfizer
$26.05 $31.32 $147.6B 18.48x $0.43 6.49% 2.33x
AMGN
Amgen
$317.17 $315.95 $170.4B 42.01x $2.38 2.88% 5.12x
ARVN
Arvinas
$8.70 $45.26 $598.3M -- $0.00 0% 2.37x
MRNA
Moderna
$34.71 $54.14 $13.4B -- $0.00 0% 4.21x
REGN
Regeneron Pharmaceuticals
$678.42 $923.05 $74.2B 17.72x $0.88 0.13% 5.50x
VKTX
Viking Therapeutics
$29.83 $99.29 $3.3B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
PFE
Pfizer
41.92% 0.618 43.87% 0.82x
AMGN
Amgen
91.09% 0.434 43.85% 0.84x
ARVN
Arvinas
0.11% 1.554 0.05% 4.58x
MRNA
Moderna
-- 0.488 -- 3.45x
REGN
Regeneron Pharmaceuticals
6.33% 0.941 2.54% 3.86x
VKTX
Viking Therapeutics
-- -1.225 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
PFE
Pfizer
$11.9B $3.2B 5.09% 8.91% 4.1% $5.8B
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $4.4B
ARVN
Arvinas
-- -$58.2M -32.92% -32.96% -98.31% -$84.4M
MRNA
Moderna
$217M -$1.2B -29.09% -29.09% -123.22% $303M
REGN
Regeneron Pharmaceuticals
$3.2B $1B 14.73% 15.78% 25.56% $995.8M
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$31.2M

Pfizer vs. Competitors

  • Which has Higher Returns PFE or AMGN?

    Amgen has a net margin of 2.31% compared to Pfizer's net margin of 6.9%. Pfizer's return on equity of 8.91% beat Amgen's return on equity of 66.87%.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    AMGN
    Amgen
    65.75% $1.16 $66B
  • What do Analysts Say About PFE or AMGN?

    Pfizer has a consensus price target of $31.32, signalling upside risk potential of 20.22%. On the other hand Amgen has an analysts' consensus of $315.95 which suggests that it could fall by -0.39%. Given that Pfizer has higher upside potential than Amgen, analysts believe Pfizer is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 13 1
    AMGN
    Amgen
    9 14 2
  • Is PFE or AMGN More Risky?

    Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Amgen has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.288%.

  • Which is a Better Dividend Stock PFE or AMGN?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.49%. Amgen offers a yield of 2.88% to investors and pays a quarterly dividend of $2.38 per share. Pfizer pays 118.44% of its earnings as a dividend. Amgen pays out 118.14% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios PFE or AMGN?

    Pfizer quarterly revenues are $17.8B, which are larger than Amgen quarterly revenues of $9.1B. Pfizer's net income of $410M is lower than Amgen's net income of $627M. Notably, Pfizer's price-to-earnings ratio is 18.48x while Amgen's PE ratio is 42.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.33x versus 5.12x for Amgen. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    2.33x 18.48x $17.8B $410M
    AMGN
    Amgen
    5.12x 42.01x $9.1B $627M
  • Which has Higher Returns PFE or ARVN?

    Arvinas has a net margin of 2.31% compared to Pfizer's net margin of -76.18%. Pfizer's return on equity of 8.91% beat Arvinas's return on equity of -32.96%.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    ARVN
    Arvinas
    -- -$0.63 $562.3M
  • What do Analysts Say About PFE or ARVN?

    Pfizer has a consensus price target of $31.32, signalling upside risk potential of 20.22%. On the other hand Arvinas has an analysts' consensus of $45.26 which suggests that it could grow by 420.27%. Given that Arvinas has higher upside potential than Pfizer, analysts believe Arvinas is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 13 1
    ARVN
    Arvinas
    13 5 0
  • Is PFE or ARVN More Risky?

    Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Arvinas has a beta of 1.954, suggesting its more volatile than the S&P 500 by 95.435%.

  • Which is a Better Dividend Stock PFE or ARVN?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.49%. Arvinas offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Arvinas pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PFE or ARVN?

    Pfizer quarterly revenues are $17.8B, which are larger than Arvinas quarterly revenues of $59.2M. Pfizer's net income of $410M is higher than Arvinas's net income of -$45.1M. Notably, Pfizer's price-to-earnings ratio is 18.48x while Arvinas's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.33x versus 2.37x for Arvinas. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    2.33x 18.48x $17.8B $410M
    ARVN
    Arvinas
    2.37x -- $59.2M -$45.1M
  • Which has Higher Returns PFE or MRNA?

    Moderna has a net margin of 2.31% compared to Pfizer's net margin of -117.16%. Pfizer's return on equity of 8.91% beat Moderna's return on equity of -29.09%.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    MRNA
    Moderna
    22.7% -$2.91 $10.9B
  • What do Analysts Say About PFE or MRNA?

    Pfizer has a consensus price target of $31.32, signalling upside risk potential of 20.22%. On the other hand Moderna has an analysts' consensus of $54.14 which suggests that it could grow by 55.97%. Given that Moderna has higher upside potential than Pfizer, analysts believe Moderna is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 13 1
    MRNA
    Moderna
    5 17 1
  • Is PFE or MRNA More Risky?

    Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

  • Which is a Better Dividend Stock PFE or MRNA?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.49%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PFE or MRNA?

    Pfizer quarterly revenues are $17.8B, which are larger than Moderna quarterly revenues of $956M. Pfizer's net income of $410M is higher than Moderna's net income of -$1.1B. Notably, Pfizer's price-to-earnings ratio is 18.48x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.33x versus 4.21x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    2.33x 18.48x $17.8B $410M
    MRNA
    Moderna
    4.21x -- $956M -$1.1B
  • Which has Higher Returns PFE or REGN?

    Regeneron Pharmaceuticals has a net margin of 2.31% compared to Pfizer's net margin of 24.22%. Pfizer's return on equity of 8.91% beat Regeneron Pharmaceuticals's return on equity of 15.78%.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    REGN
    Regeneron Pharmaceuticals
    85.08% $8.06 $31.3B
  • What do Analysts Say About PFE or REGN?

    Pfizer has a consensus price target of $31.32, signalling upside risk potential of 20.22%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $923.05 which suggests that it could grow by 36.06%. Given that Regeneron Pharmaceuticals has higher upside potential than Pfizer, analysts believe Regeneron Pharmaceuticals is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 13 1
    REGN
    Regeneron Pharmaceuticals
    12 6 0
  • Is PFE or REGN More Risky?

    Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.270, suggesting its less volatile than the S&P 500 by 72.991%.

  • Which is a Better Dividend Stock PFE or REGN?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.49%. Regeneron Pharmaceuticals offers a yield of 0.13% to investors and pays a quarterly dividend of $0.88 per share. Pfizer pays 118.44% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PFE or REGN?

    Pfizer quarterly revenues are $17.8B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3.8B. Pfizer's net income of $410M is lower than Regeneron Pharmaceuticals's net income of $917.7M. Notably, Pfizer's price-to-earnings ratio is 18.48x while Regeneron Pharmaceuticals's PE ratio is 17.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.33x versus 5.50x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    2.33x 18.48x $17.8B $410M
    REGN
    Regeneron Pharmaceuticals
    5.50x 17.72x $3.8B $917.7M
  • Which has Higher Returns PFE or VKTX?

    Viking Therapeutics has a net margin of 2.31% compared to Pfizer's net margin of --. Pfizer's return on equity of 8.91% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    PFE
    Pfizer
    66.74% $0.07 $152.1B
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About PFE or VKTX?

    Pfizer has a consensus price target of $31.32, signalling upside risk potential of 20.22%. On the other hand Viking Therapeutics has an analysts' consensus of $99.29 which suggests that it could grow by 232.87%. Given that Viking Therapeutics has higher upside potential than Pfizer, analysts believe Viking Therapeutics is more attractive than Pfizer.

    Company Buy Ratings Hold Ratings Sell Ratings
    PFE
    Pfizer
    6 13 1
    VKTX
    Viking Therapeutics
    9 1 0
  • Is PFE or VKTX More Risky?

    Pfizer has a beta of 0.613, which suggesting that the stock is 38.72% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.903, suggesting its less volatile than the S&P 500 by 9.651%.

  • Which is a Better Dividend Stock PFE or VKTX?

    Pfizer has a quarterly dividend of $0.43 per share corresponding to a yield of 6.49%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pfizer pays 118.44% of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios PFE or VKTX?

    Pfizer quarterly revenues are $17.8B, which are larger than Viking Therapeutics quarterly revenues of --. Pfizer's net income of $410M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Pfizer's price-to-earnings ratio is 18.48x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pfizer is 2.33x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    PFE
    Pfizer
    2.33x 18.48x $17.8B $410M
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is CyberArk The Next Big Cybersecurity Stock?
Is CyberArk The Next Big Cybersecurity Stock?

CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock